ライフサイエンスコーパス: cancer chemotherapy

1 of oxaliplatin neuropathy (a complication of cancer chemotherapy).

2 ess disease relapse after 5-FU-based gastric cancer chemotherapy.

3 ibitors that may also serve as new leads for cancer chemotherapy.

4 istance (MDR) is a major cause of failure of cancer chemotherapy.

5 n might be a simple yet effective adjunct to cancer chemotherapy.

6 s, including a variety of drugs used in anti-cancer chemotherapy.

7 DXR and identify RGS6 as a novel target for cancer chemotherapy.

8 (MDR) has decreased the hope for successful cancer chemotherapy.

9 ding the emergence of drug resistance during cancer chemotherapy.

10 resistance (MDR) is a barrier to successful cancer chemotherapy.

11 e-2,6-bisphosphatase, an emerging target for cancer chemotherapy.

12 bition of SET may have beneficial effects in cancer chemotherapy.

13 he mitotic spindle is a validated target for cancer chemotherapy.

14 SUMO1 appears to be a new target pathway for cancer chemotherapy.

15 Febrile neutropenia commonly complicates cancer chemotherapy.

16 rs currently being sought as an adjuvant for cancer chemotherapy.

17 eed for new molecular targets for pancreatic cancer chemotherapy.

18 ymerization and shows remarkable efficacy in cancer chemotherapy.

19 PA) is a DNA alkylating agent widely used in cancer chemotherapy.

20 is linked to tumour multidrug resistance in cancer chemotherapy.

21 pment of antibody-drug conjugates (ADCs) for cancer chemotherapy.

22 pase activation, thus having implications in cancer chemotherapy.

23 iated targeting of this pathway can optimize cancer chemotherapy.

24 that T115 is a potential drug candidate for cancer chemotherapy.

25 ains a major challenge to successful ovarian cancer chemotherapy.

26 ure of both molecular diagnostics as well as cancer chemotherapy.

27 , thus representing an attractive target for cancer chemotherapy.

28 nhibitors can emerge as a unique paradigm in cancer chemotherapy.

29 resent a class of nucleoside analogs used in cancer chemotherapy.

30 lymerization inhibitors for potential use in cancer chemotherapy.

31 ar targets (molecular targets) important for cancer chemotherapy.

32 he variable efficacy of antimitotic drugs in cancer chemotherapy.

33 both p53 and Rb is important for efficacy of cancer chemotherapy.

34 ing normal tissue is critically important in cancer chemotherapy.

35 livery systems for targeted and personalized cancer chemotherapy.

36 nt implications for the individualization of cancer chemotherapy.

37 DNA-damaging agents are extensively used for cancer chemotherapy.

38 livered dose intensity in patients receiving cancer chemotherapy.

39 of modulation of this signaling pathway for cancer chemotherapy.

40 nd ABCC1/MRP1 causes multidrug resistance in cancer chemotherapy.

41 itize ABCC1/MRP1-mediated drug resistance in cancer chemotherapy.

42 erior to angiostatin and may be exploited in cancer chemotherapy.

43 Paclitaxel is an active agent used in breast cancer chemotherapy.

44 represent major dose-limiting toxicities of cancer chemotherapy.

45 esistance is a serious problem in successful cancer chemotherapy.

46 tion, oxidative stress, and certain types of cancer chemotherapy.

47 ning is a promising avenue for innovation in cancer chemotherapy.

48 lly valid marker of viable cell number after cancer chemotherapy.

49 rently being evaluated in clinical trials as cancer chemotherapy.

50 major success in the era of target-directed cancer chemotherapy.

51 ce and its potential modulation for improved cancer chemotherapy.

52 ounting for their widespread use in clinical cancer chemotherapy.

53 ules has shown potential as a new avenue for cancer chemotherapy.

54 regulation and are an attractive target for cancer chemotherapy.

55 rent drugs, remains an unsolved challenge in cancer chemotherapy.

56 tinues to be a major impediment to effective cancer chemotherapy.

57 uration of neutropenia in patients receiving cancer chemotherapy.

58 icin is an anthracycline antibiotic used for cancer chemotherapy.

59 f microtubules is an important mechanism for cancer chemotherapy.

60 that IDO inhibitors may improve responses to cancer chemotherapy.

61 substances that are of potential interest in cancer chemotherapy.

62 nes that may enable the individualization of cancer chemotherapy.

63 zyme in DNA synthesis and a major target for cancer chemotherapy.

64 ll and developmental biology, nutrition, and cancer chemotherapy.

65 duce apoptosis and may be exploited for anti-cancer chemotherapy.

66 inhibitors may be a powerful new approach to cancer chemotherapy.

67 exate is one of the most successful drugs in cancer chemotherapy.

68 development of an optimal ribonuclease-based cancer chemotherapy.

69 the major dose-limiting toxicity of systemic cancer chemotherapy.

70 erase inhibitors are a powerful strategy for cancer chemotherapy.

71 ult in the lack of efficacy of many drugs in cancer chemotherapy.

72 emonstrated the potential efficacy of TPA in cancer chemotherapy.

73 otic agent that has been used extensively in cancer chemotherapy.

74 ization for serious toxicity associated with cancer chemotherapy.

75 atin,is an important problem to be solved in cancer chemotherapy.

76 e that is associated with a poor response to cancer chemotherapy.

77 nd their validation as potential targets for cancer chemotherapy.

78 ational modification may serve as a possible cancer chemotherapy.

79 nding has significant implications for human cancer chemotherapy.

80 ic uptake inhibitors treatment during breast cancer chemotherapy.

81 quent and potentially severe complication of cancer chemotherapy.

82 r interstitium are of critical importance in cancer chemotherapy.

83 ntially nonimmunogenic approach for targeted cancer chemotherapy.

84 ve force to overcome multidrug resistance in cancer chemotherapy.

85 ntisense technology may play a major role in cancer chemotherapy.

86 y of topoisomerase II inhibitors in clinical cancer chemotherapy.

87 as cisplatin, have been used extensively in cancer chemotherapy.

88 ceptibility to stress such as that caused by cancer chemotherapy.

89 nds for the development of isoform-selective cancer chemotherapy.

90 ar topoisomerase I is an important target in cancer chemotherapy.

91 r anticonvulsants compromise the efficacy of cancer chemotherapy.

92 several toxic agents including radiation and cancer chemotherapy.

93 hancing the effectiveness of these agents in cancer chemotherapy.

94 vity is emerging as an attractive target for cancer chemotherapy.

95 gs such as methotrexate are commonly used in cancer chemotherapy.

96 herapy and the cytotoxicity of some forms of cancer chemotherapy.

97 alkaloids and taxol, are routinely used for cancer chemotherapy.

98 currently undergoing clinical evaluation for cancer chemotherapy.

99 , is arguably the most important new drug in cancer chemotherapy.

100 l agents, many of which are commonly used in cancer chemotherapy.

101 jor factor limiting the continued success of cancer chemotherapy.

102 stance is a major obstacle to the success of cancer chemotherapy.

103 ional structure and is a potential agent for cancer chemotherapy.

104 tant determinant of the clinical efficacy of cancer chemotherapy.

105 on is a promising new strategy for improving cancer chemotherapy.

106 igand, 3-IAABU could be a promising agent in cancer chemotherapy.

107 tance of these cells to the toxic effects of cancer chemotherapy.

108 tered immediately after extravasation during cancer chemotherapy.

109 ions induced by carcinogens or drugs used in cancer chemotherapy.

110 the major obstacles to long term successful cancer chemotherapy.

111 mustards and mitomycin C, are used widely in cancer chemotherapy.

112 g well-defined metallo-helical complexes for cancer chemotherapy.

113 pharmacodynamic biomarkers for anti-mitotic cancer chemotherapy.

114 ells and as a promising target to potentiate cancer chemotherapy.

115 epresents a promising strategy to potentiate cancer chemotherapy.

116 er surgical procedures and immunosuppressing cancer chemotherapy.

117 d as an appealing alternative to traditional cancer chemotherapy.

118 mily, and continue to be extensively used in cancer chemotherapy.

119 in (DOX) is an anthracycline used widely for cancer chemotherapy.

120 ive fungal infections (IFIs) that complicate cancer chemotherapy.

121 st toxicity is one of the main challenges of cancer chemotherapy.

122 expression and represent valuable targets in cancer chemotherapy.

123 continue to deliver productive pipelines for cancer chemotherapy.

124 ins one of the most serious complications of cancer chemotherapy.

125 uced a patient cohort requiring both HIV and cancer chemotherapy.

126 ations for mechanisms of cell killing during cancer chemotherapy.

127 promising therapeutic approach for prostate cancer chemotherapy.

128 ule-stabilizing agent that is widely used in cancer chemotherapy.

129 nblastine and vincristine, which are used in cancer chemotherapy.

130 ucleoside analogs for oral administration in cancer chemotherapy.

131 istance (MDR) is a major cause of failure in cancer chemotherapy.

132 tion (EF) and volumes in patients undergoing cancer chemotherapy.

133 orable treatment outcomes in cisplatin-based cancer chemotherapy.

134 toxicity which remains a major limitation in cancer chemotherapy.

135 (SETMAR) mediates resistance to DNA damaging cancer chemotherapy.

136 ising approach to increasing the efficacy of cancer chemotherapy.

137 e formation of multidrug resistance (MDR) in cancer chemotherapy.

138 forts to target the CXCL12-CXCR4 pathway for cancer chemotherapy.

139 epresents a novel mitotic spindle target for cancer chemotherapy.

140 ole of hCtr1 in platinum-drug sensitivity in cancer chemotherapy.

141 resulting in an attenuated response to anti-cancer chemotherapy.

142 he further development of LSF inhibitors for cancer chemotherapy.

143 toxic side effects commonly associated with cancer chemotherapies.

144 kely to unravel additional targets for novel cancer chemotherapies.

145 d potentially enhance the efficacy of extant cancer chemotherapies.

146 g delivery systems for personalized targeted cancer chemotherapies.

147 crease effectiveness of proteasome inhibitor cancer chemotherapies.

148 (ICL), a property exploited by several anti-cancer chemotherapies.

149 his frequently encountered adverse effect of cancer chemotherapies.

150 step toward studying the pharmacogenetics of cancer chemotherapy, 51 candidate genes from the pathway

151 ne of the most successful drugs ever used in cancer chemotherapy, acting against a variety of cancer

152 nces the activation of p53 by a DNA-damaging cancer chemotherapy agent in a synergistic fashion.

153 Cisplatin is a highly effective cancer chemotherapy agent.

154 Cisplatin is one of the most widely used cancer chemotherapy agents, but its mechanism of action

155 oxorubicin (DXR), among the most widely used cancer chemotherapy agents, promotes cancer cell death v

156 ing cassette transporters to the toxicity of cancer chemotherapy agents, we have used mice geneticall

157 associated with end-stage renal failure and cancer chemotherapy, also has pleiotropic properties.

158 al neuropathy is dose limiting in paclitaxel cancer chemotherapy and can result in both acute pain du

159 rentiation, and apoptosis, is a strategy for cancer chemotherapy and chemoprevention, and 3-amino-6-(

160 ddress the problem of drug resistance during cancer chemotherapy and explore the possibility of manip

161 of polyamine levels is a viable strategy for cancer chemotherapy and for the treatment of parasitic d

162 Crosslinking agents are widely used in cancer chemotherapy and form an array of structurally di

163 how to circumvent this resistance to improve cancer chemotherapy and have implications for pharmacoki

164 which the antitumor effects of conventional cancer chemotherapy and immunotherapy are realized.

165 n patients with short-bowel syndrome, during cancer chemotherapy and in bone marrow transplantation,

166 ance of tumours to alkylating agents used in cancer chemotherapy and its inactivation is therefore of

167 cyclines and etoposide are commonly used for cancer chemotherapy and kill tumor cells by causing accu

168 rvival in cancer cells with implications for cancer chemotherapy and novel drug discovery.

169 floxacin on cycle 1 only of myelosuppressive cancer chemotherapy and on subsequent cycles after a cyc

170 herent risk of acute renal failure (ARF; eg, cancer chemotherapy and organ transplantation), the goal

171 ion has a novel therapeutic role in prostate cancer chemotherapy and prognosis.

172 rties permitting them to survive traditional cancer chemotherapy and radiation therapy.

173 alence of topoisomerase II-targeted drugs in cancer chemotherapy and the impact of drug resistance on

174 pproach may reduce both the doses needed for cancer chemotherapy and the side effects in tissues with

175 are to counteract the nausea associated with cancer chemotherapy and to stimulate appetite.

176 preparations to treat nausea associated with cancer chemotherapy and to stimulate appetite.

177 idrug efflux pumps cause serious problems in cancer chemotherapy and treatment of bacterial infection

178 activity is a common and successful tool in cancer chemotherapy and treatment of other diseases.

179 eful in combating the nausea associated with cancer chemotherapy, and alosetron is employed in the tr

180 ospitalization rate for toxicity from breast cancer chemotherapy, and even large clinical trials ofte

181 uman immunodeficiency virus (HIV) infection, cancer chemotherapy, and hematopoietic stem cell transpl

182 ighly tumorigenic, resistant to conventional cancer chemotherapy, and responsible, at least in part,

183 g: ICL-inducing agents are powerful tools in cancer chemotherapy, and spontaneous ICLs have recently

184 uently induced by medical treatments such as cancer chemotherapy, antirejection drugs used in organ t

185 ncapsulated drugs that have shown promise in cancer chemotherapy are administered intravenously.

186 Although side effects of cancer chemotherapy are well known, "opposite effects" o

187 The benefit of cancer chemotherapy based on alkylating agents is limite

188 Current antimitotic cancer chemotherapy based on vinca alkaloids and taxanes

189 ation of TR3 as a drug target for pancreatic cancer chemotherapy, based on the ability of TR3 inhibit

190 ylase (TP) is an important target enzyme for cancer chemotherapy because it is expressed at high leve

191 th some advances in modern medicine (such as cancer chemotherapy, broad exposure to antibiotics, and

192 GART) (EC 2.1.2.2) is a validated target for cancer chemotherapy, but mechanistic studies of this the

193 (hTS) has been extensively investigated for cancer chemotherapy, but several aspects of its activity

194 ptotic bax gene may be a valuable adjunct to cancer chemotherapy by diminishing survival of p53-defic

195 onmental exposure, endogenous metabolism and cancer chemotherapy can give rise to alkylation of DNA,

196 inib, two agents already used clinically for cancer chemotherapy, can inhibit this activity suggest t

197 Many effective agents used in cancer chemotherapy cause DNA interstrand crosslinks (IC

198 2 (HER2/NEU) signaling, a mainstay of breast cancer chemotherapy, cause dilated cardiomyopathy in man

199 Breast cancer chemotherapy decisions in patients > or = 65 year

200 tion damage resistance, which is critical in cancer chemotherapy, depends on the overexpression of al

201 NAs synergized with the frontline colorectal cancer chemotherapy drug irinotecan.

202 Doxorubicin, a widely used cancer chemotherapy drug, induces disruption of the hair

203 We conjugate paclitaxel (PTX), a widely used cancer chemotherapy drug, to branched polyethylene glyco

204 Cytotoxic cancer chemotherapy drugs are believed to gain selectivi

205 xorubicin) and 4'-epidaunorubicin, important cancer chemotherapy drugs, has been developed for Strept

206 rvival and inhibits apoptosis in response to cancer chemotherapy drugs.

207 e 3-kinase (PI3K) is an important target for cancer chemotherapy due to the deregulation of its signa

208 Many agents successfully used in cancer chemotherapy either directly or indirectly covale

209 tients who have fever and neutropenia during cancer chemotherapy, empirical therapy with oral ciprofl

210 ration and the benefits of dose-dense breast cancer chemotherapy, especially for hormone receptor (HR

211 of adaptive resistance is key to overcoming cancer chemotherapy failure.

212 hile combination therapies are a mainstay of cancer chemotherapy, few studies have addressed the comb

213 parameters in 1,504 patients during or after cancer chemotherapy for 3 clinically-relevant scenarios.

214 Bleomycin is an antibiotic used in cancer chemotherapy for its ability to achieve both sing

215 ve or minimally active disease who are given cancer chemotherapy for lymphoma or leukemia.

216 drugs have the potential to greatly advance cancer chemotherapy for new theranostics and drug-delive

217 NA cross-linking agent that has been used in cancer chemotherapy for over 20 years, yet little is kno

218 f THC derivatives for nausea associated with cancer chemotherapy, glaucoma, stimulation of appetite,

219 The design of cancer chemotherapy has become increasingly sophisticate

220 Drug resistance that occurs during cancer chemotherapy has been a major problem in controll

221 Cancer chemotherapy has evolved from cytotoxic agents an

222 Research on controlled drug delivery for cancer chemotherapy has focused mainly on ways to delive

223 tween individuals in the pharmacokinetics of cancer chemotherapy has important consequences in terms

224 trials employing synthetic MMP inhibitors in cancer chemotherapy has led us to hypothesize that some

225 ermal growth factor receptor as a target for cancer chemotherapy has proven to be an effective treatm

226 ine-DNA complex, which is a potent agent for cancer chemotherapy, has a unique intercalating molecula

227 Conventional cancer chemotherapy heavily relies on the use of cytotox

228 cern when these people are exposed to either cancer chemotherapy, immunosuppressive or biologic thera

229 nase I (HAI) is a potential protein drug for cancer chemotherapy, in that it is capable of depleting

230 B overexpression also mediated resistance to cancer chemotherapy, in this case through interactions w

231 drugs, the issue is especially critical for cancer chemotherapy, in which a narrow therapeutic index

232 There are many obstacles to effective cancer chemotherapy, including drug penetration and accu

233 Microtubule inhibitors, widely used in cancer chemotherapy, induce G2-M arrest and apoptosis an

234 a critical target for prevention of chronic cancer chemotherapy-induced neuropathic pain.

235 Cancer chemotherapy is almost always applied to patients

236 Multidrug resistance during cancer chemotherapy is commonly acquired by overexpressi

237 rboxamides as resistance-modifying agents in cancer chemotherapy is described.

238 The efficacy of cisplatin in cancer chemotherapy is limited by the development of res

239 related apoptosis-inducing ligand (TRAIL) in cancer chemotherapy is not fully understood.

240 Traditional cancer chemotherapy is often accompanied by systemic tox

241 Development of drug resistance during cancer chemotherapy is one of the major causes of chemot

242 Although many observers believe that cancer chemotherapy is overused at the end of life, ther

243 One of the least well understood problems in cancer chemotherapy is the cross-resistance of certain t

244 The central problem in cancer chemotherapy is the severe toxic side effects of

245 Medicare beneficiaries received recommended cancer chemotherapy less frequently than other Medicare

246 els have been a major therapeutic target for cancer chemotherapy, little is known regarding the stepw

247 The treatment of older patients with cancer chemotherapy may be as effective as it is in youn

248 mutations caused by cytotoxic agents used in cancer chemotherapy may cause secondary malignancies as

249 ning suitable drugs and approaches for human cancer chemotherapy mediated by DT-diaphorase.

250 f a novel adjunctive therapy that could make cancer chemotherapy more effective.

251 ational drug development effort known as the Cancer Chemotherapy National Service Center.

252 To limit the adverse side effects of cancer chemotherapy on healthy organs, we proposed a dru

253 ecommended for persons with HBsAg undergoing cancer chemotherapy or transplantation, but major questi

254 uppressor mechanism and a key determinant of cancer chemotherapy outcome.

255 n-6, and the neuropathic pain induced by the cancer chemotherapy paclitaxel.

256 In rats exposed to either of 2 neurotoxic cancer chemotherapies, paclitaxel or oxaliplatin, or to

257 C (PKC), a validated therapeutic target for cancer chemotherapy, provides a paradigm for assessing s

258 observed in CD4-depleted patients receiving cancer chemotherapy (r = -0.65, P =.009).

259 rall, 17.3% of the elderly women with breast cancer chemotherapy received filgrastim and 6.8% receive

260 tions regarding the use of ATR inhibitors in cancer chemotherapy regimens.

261 ify potential mechanisms underlying prostate cancer chemotherapy response and resistance, we compared

262 pite its proven efficacy in treating ovarian cancer, chemotherapy seems to be used less among patient

263 ion of NF-kappaB activation as an adjunct to cancer chemotherapy should be approached with caution.

264 uggesting that certain current approaches to cancer chemotherapy should be modified.

265 ed as poor prognostic factors for successful cancer chemotherapy, strategies that use antiapoptotic f

266 a three-arm, phase III, advanced colorectal cancer chemotherapy study exploring combinations of irin

267 ession and that some conventional colorectal cancer chemotherapy supports the immunosuppressive tumor

268 eins (ATLs) share functional motifs with the cancer chemotherapy target O(6)-alkylguanine-DNA alkyltr

269 in cell division, which makes them important cancer chemotherapy targets.

270 on surgical procedures and immunosuppressing cancer chemotherapies that rely on antibiotic prophylaxi

271 During cancer chemotherapy, the administration of therapeutics

272 The two-drug model has implications for cancer chemotherapy, the cellular processing of etoposid

273 fluence treatment efficacy in platinum-based cancer chemotherapy through hCtr1 regulation.

274 g clinical therapeutics in broad areas, from cancer chemotherapy to antipsychotics and antidepressant

275 Bacterial asparaginases are used in cancer chemotherapy to deplete asparagine from the blood

276 cancer drugs is an emerging new strategy for cancer chemotherapy to increase antitumor responses.

277 The goal of palliative cancer chemotherapy treatment is to prolong survival and

278 ion properties, which can be used to improve cancer chemotherapy treatments.

279 ding properties of this enzyme for improving cancer chemotherapy treatments.

280 in human cancers, and are targets of ongoing cancer chemotherapy trials.

281 ularly relevant to cancer treatment, as most cancer chemotherapies trigger mitochondrial-mediated apo

282 ision styles are each associated with breast cancer chemotherapy use.

283 t of drug resistance is a major challenge in cancer chemotherapy using doxorubicin.

284 of febrile neutropenia in patients receiving cancer chemotherapy utilizing the myeloid growth factors

285 ment of a rationally designed potentiator of cancer chemotherapy, via inhibition of Bcl-X(L) function

286 g women with LN-positive, ER-negative breast cancer, chemotherapy was associated with a significant r

287 Among patients who died of cancer, chemotherapy was used frequently in the last 3 m

288 To reveal the antiangiogenic capability of cancer chemotherapy, we developed an alternative antiang

289 To improve cancer chemotherapy, we need to understand the mechanism

290 th acquired drug resistance against standard cancer chemotherapies were more sensitive to WL-276 than

291 This is particularly relevant to cancer chemotherapy, when the risk of toxicity must be b

292 plantation, treatment of preterm babies, and cancer chemotherapy, which we today take for granted, wo

293 cancer growth and are potential targets for cancer chemotherapy with ASCT2 (SLC1A5) being investigat

294 esin Eg5 is a target for drug development in cancer chemotherapy with compounds in phase II clinical

295 Cancer chemotherapy with methotrexate (MTX) is known to

296 ide use of microtubule-interfering agents in cancer chemotherapy with promising results.

297 tion may identify a unique mechanism whereby cancer chemotherapy with receptor tyrosine kinase inhibi

298 may provide an enhanced clinical strategy in cancer chemotherapy with this new agent.

299 further validated them as potential foci for cancer chemotherapy, with several additional PI3K effect

300 is the most commonly used drug in colorectal cancer chemotherapy, yet development of drug resistance